arrow
J

Jin Won Kim

kwangwoon university
H指数:45
被引数:9,699

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

PAK4 orchestrates dual transcriptional and post-translational repression of E-cadherin to promote epithelial-to-mesenchymal transition and invasiveness in pancreatic cancer

PAK4通过协调双重转录和翻译后抑制E-钙黏蛋白以促进胰腺癌的上皮-间质转化和侵袭性

2026-10-310
OAAI
Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial

曲妥珠单抗联合纳武利尤单抗与吉西他滨和顺铂作为HER2阳性不可切除胆道癌的一线疗法:一项1b/2期临床试验

2026-09-220
OAAI
Prognostic stratification of patients with biliary tract cancer treated with chemoimmunotherapy: A retrospective multicenter real-world study

胆道癌患者接受化疗免疫疗法后的预后分层:一项回顾性多中心真实世界研究

Cancer
IF5.1
2026-09-160
PRE
Prognostic Role of Adverse Events in a Worldwide Population of Patients with Biliary Tract Cancer Treated with Chemo-Immunotherapy

胆道癌患者接受化疗免疫疗法治疗后不良事件预测作用的全球人群研究

Cancers
IF4.4
2026-09-100
OA
Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real-World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab

探索系统性治疗后的手术治疗在局部晚期胆道癌中的作用:来自接受顺铂、吉西他滨和度伐利尤单抗治疗的大型回顾性跨国真实世界队列的结局

2026-08-150
PRE
Vactosertib plus pembrolizumab in patients with non-microsatellite instability-high metastatic colorectal or gastric cancer: a multicenter, phase Ib/IIa study

Vactosertib联合pembrolizumab治疗非微卫星不稳定性高转移性结直肠癌或胃癌患者的多中心、 Ib/IIa期研究

2026-07-210
OA
Survival Rates of Patients with Gastric Cancer According to Age and Sex: A Large-Scale Study Using Data from 14,739 Patients

胃癌患者的生存率按年龄和性别划分:一项基于14,739例患者数据的大规模研究

2026-01-014
OAAI
Pilot Study for Feasibility of Onco-Geriatric Intervention Model in Older Patients with Cancer in a Tertiary Academic Hospital

在三级教学医院中针对老年癌症患者开展肿瘤-老年干预模型的可行性初步研究

2026-01-010
OA
Genomic Pathway Alterations and Their Prognostic Impact in Biliary Tract Cancer: Insights from a Multinational Cohort Treated with Cisplatin, Gemcitabine, and Durvalumab

基因组通路改变及其在胆道癌中的预后影响:来自接受顺铂、吉西他滨和度伐利尤单抗治疗的跨国队列的见解

2025-10-030
PRE
Multicenter phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab

多中心II期临床试验,评估仑伐替尼在经一线阿替利珠单抗联合贝伐珠单抗治疗后进展的晚期肝细胞癌患者中的应用。

2025-09-040
OAAI
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population

接受顺铂、吉西他滨和度伐利尤单抗治疗的晚期胆道癌患者中分子改变的影响:一项大型、真实世界、全球性人群研究

2025-09-011
PRE
Early growth response 1 as a key regulator of PD-L1 expression and immune evasion in extranodal NK/T-cell lymphoma

早期生长反应1作为PD-L1表达和免疫逃逸的关键调节因子在结外NK/T细胞淋巴瘤中的作用

2025-06-130
OAAI
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer

候选替代终点与晚期胆道癌总生存率的关系

2025-06-030
PRE